Baseline characteristics of the study population
| Characteristic | Total (n=6016) | Non-CHIP (N=5796) | CHIP (N=220) | P value |
| Age (years), median (IQR) | 62.0 (54.0–70.0) | 62.0 (53.0–69.0) | 68.0 (60.0–75.0) | <0.0001 |
| age, n (%) | <0.0001 | |||
| <40 | 171 (2.8) | 170 (2.9) | 1 (0.5) | |
| 40–49 | 700 (11.6) | 687 (11.9) | 13 (5.9) | |
| 50–59 | 1613 (26.8) | 1578 (27.2) | 35 (15.9) | |
| 60–69 | 2017 (33.5) | 1946 (33.6) | 71 (32.3) | |
| 70–79 | 1186 (19.7) | 1122 (19.4) | 64 (29.1) | |
| ≥80 | 329 (5.5) | 293 (5.1) | 36 (16.4) | |
| Female, n (%) | 1863 (31.0) | 1779 (30.7) | 84 (38.2) | 0.02 |
| BMI (kg/m2), mean±SD | 24.7±3.4 | 24.7±3.4 | 24.7±3.6 | 0.38 |
| Current smoking, n (%) | 2046 (34.0) | 1990 (34.3) | 56 (25.5) | 0.01 |
| Drinking, n (%) | 1077 (17.9) | 1052 (18.2) | 25 (11.4) | 0.01 |
| Medical history, n (%) | ||||
| CHD | 548 (9.1) | 528 (9.1) | 20 (9.1) | 0.99 |
| Hypertension | 3596 (59.8) | 3462 (59.7) | 134 (60.9) | 0.73 |
| Diabetes mellitus | 1320 (21.9) | 1270 (21.9) | 50 (22.7) | 0.77 |
| Hypercholesterolaemia | 430 (7.1) | 412 (7.1) | 18 (8.2) | 0.54 |
| NIHSS | ||||
| Median (IQR) | 3.0 (2.0–6.0) | 3.0 (2.0–6.0) | 3.0 (2.0–6.0) | 0.76 |
| TOAST classification, n (%) | ||||
| LAA | 1570 (26.1) | 1515 (26.1) | 55 (25.0) | 0.12 |
| CE | 357 (5.9) | 341 (5.9) | 16 (7.3) | |
| SAO | 1463 (24.3) | 1424 (24.6) | 39 (17.7) | |
| SOE | 68 (1.1) | 66 (1.1) | 2 (0.9) | |
| SUE | 2558 (42.5) | 2450 (42.3) | 108 (49.1) | |
| Time from symptom onset to arrive at hospital | 1.0±1.4 | 1.0±1.4 | 0.9±1.4 | 0.18 |
BMI, body mass index; CE, cardioembolism; CHD, coronary heart disease; CHIP, clonal haematopoiesis of indeterminate potential; LAA, large artery atherosclerosis; NIHSS, National Institutes of Health Stroke Scale Score; SAO, small artery occlusion; SOE, stroke of other determined aetiology; SUE, stroke of undetermined aetiology.; TOAST, Trial Org 10 172 in Acute Stroke Treatment.